The Technical AnalystExchange: OTC Sector: Healthcare Industry: Drug Manufacturers—General
Chugai Pharmaceutical Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.97% $16.62
America/New_York / 3 mai 2024 @ 15:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 54 693 mill |
| EPS: | 0.640 |
| P/E: | 25.97 |
| Earnings Date: | Jul 25, 2024 |
| SharesOutstanding: | 3 290.77 mill |
| Avg Daily Volume: | 0.186 mill |
| RATING 2024-05-03 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.89x |
| Company: PE 25.97 | sector: PE 29.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.62x |
| Company: PE 25.97 | industry: PE 41.65 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$34.85 (109.68%) $18.23 |
| Date: 2024-05-06 |
| Expected Trading Range (DAY) |
|---|
|
$ 15.80 - 17.44 ( +/- 4.91%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $16.62 (0.97% ) |
| Volume | 0.0668 mill |
| Avg. Vol. | 0.186 mill |
| % of Avg. Vol | 35.86 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CHGCY
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CHGCY
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.
Latest News
